Oppenheimer Upgrades Cubist Pharmaceuticals To Outperform, $37 PT

April 20, 2011 8:24 AM | 7 seconds read |
Oppenheimer has upgraded Cubist Pharmaceuticals CBST from Perform to Outperform and has established a $37 price target.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: UpgradesPrice TargetAnalyst RatingsBiotechnologycubist pharmaceuticalsHealth CareOppenheimer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!